1990s trial gave early danger signs for asthma drugs

by John Fauber

The troubled history of asthma drugs known as long-acting beta-agonists goes back to the 1990s when a large clinical trial in Great Britain of the GlaxoSmithKline drug Serevent produced disturbing results.

In that 16-week trial of 25,000 , 12 people getting the drug died of and respiratory causes, compared with only two in the who took a standard medication, according to a 1993 paper.

In addition, there were 193 hospitalizations or life-threatening events related to asthma and respiratory causes in the users of the new drug, compared with 102 in the other group.

The serious concerns raised in the first trial of Serevent, also known as salmeterol, led to a second large study of the drug several years later in the United States.

That trial was halted by , in part because of excess deaths among African-Americans.

Researchers had hoped to study 60,000 people in the trial, but only 26,000 people had been enrolled when it was stopped in 2003.

A 2006 paper that detailed the results of the U.S. trial noted there were 37 asthma and respiratory related deaths in those receiving salmeterol, compared with 14 among those on usual who also got a placebo.

Among African-Americans getting salmeterol, 15 died of asthma and respiratory causes during the 28-week study period, compared with only three who got a placebo.

It is not known why African-Americans may be more vulnerable to the effects of salmeterol. One theory involves genetic variations in cells in the lungs.

Long-acting beta-agonists are inhaled drugs that are sold as single agents. They also can be combined in an with a steroid.

The leading beta-agonist/steroid combination product is Advair, sales of which have topped $4 billion a year since 2007, according to the market research firm IMS Health.

Another long-acting beta-agonist, Foradil (formoterol) also is available as a single-agent and as the combined product Symbicort, made by AstraZeneca.

In an email, GlaxoSmithKline spokeswoman Karen Collins said studies consistently have shown that Advair provides better overall asthma control than just an inhaled corticosteroid, including improvements in lung function, symptom control and less use of short-acting rescue inhalers.

She said both Advair and Serevent have improved asthma care.

"These medicines are used by millions of people worldwide and in the vast majority of people treated, they are well tolerated," she said.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA issues warning on 4 widely-used asthma drugs

Feb 18, 2010

(AP) -- The government is issuing new restrictions on some widely used long-acting asthma drugs, saying they should never be used without other asthma controllers to prevent a lifethreatening risk.

Recommended for you

Vaccine proves effective against deadly Middle East virus

15 hours ago

(Medical Xpress)—A vaccine developed by an international team of scientists led by the University of Pittsburgh School of Medicine successfully protects mice against a contagious and deadly virus spreading across the Middle ...

New study looks at improving vaccine awareness

16 hours ago

The best medical therapies won't do much good if the public abstains from using them. Resistance to life-saving interventions may have a variety of root causes, particularly if the biotechnology involved is new and poorly ...

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

User comments